Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Methods: The NCG mouse subcutaneous xenograft model (MGC803 cell line) was employed, with cadonilimab administered via intraperitoneal injection. The dosing regimen was as follows: the first three doses at 1 mg/kg (initiated on day 4 post-grouping, twice weekly for three consecutive weeks), followed by six doses at 5 mg/kg (twice weekly for six consecutive weeks).
Result: Cadonilimab demonstrated significant anti-tumor efficacy when combined with chemotherapy, but exhibited limited effectiveness when used alone.[1]